Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

of leasehold

improvements - - 1,030

Depreciation and amortization 297 321 3,115

In-process research and

development - - 418

Total operating expenses 10,232 12,448 144,638

Loss from operations (10,232) (9,288) (139,694)

Other income (expenses):

Interest income 693 1,702 9,643

Interest expense (92) (70) (1,500)

Change in fair value of

warrant liability (64) - (454)

Other expense - - (1,180)

Loss before tax benefit (9,695) (7,656) (133,185)

(Provision for)/benefit

from income taxes - (75) 620

Net loss (9,695) (7,731) (132,565)

Deemed dividend - - (19,424)

Preferred stock accretion (41) - (802)

Net loss attributable to

common stockholders $(9,736) $ (7,731) $(152,791)

Net loss attributable to

common stockholders per

common share - basic and

diluted $ (10.21) $(0.34)

Weighted-average common

shares outstanding -

basic and diluted 953,959 22,412,689

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2008

(Unaudited)

(In thousands, except share and per share amounts) <
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it intends to file ... and Drug Administration,(FDA) for its innovative, anti-infective ... reviewing the data from our recently completed ...
... Life Science,Network has announced today that it will ... and measurable new life science business,for Michigan companies. ... the Michigan Virtual,Medical Device Company, LLC will launch ... the MichBio Expo annual convention in Lansing, Michigan.,MichBio ...
... Oct. 9 PARI Respiratory Equipment,s,breath-enhanced nebulizer, ... compressor,deliver Dey, L.P.,s new COPD medication, Perforomist ... is a subsidiary of Mylan Inc.,(NYSE: ... Solution is indicated for,long-term, twice-daily maintenance treatment ...
Cached Biology Technology:Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 3Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 4Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 5Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 6Michigan Life Science Network to Form Two New Virtual Companies 2Michigan Life Science Network to Form Two New Virtual Companies 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 4
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... protected and tended her eggs until they hatched 4.5 ... 2014 in the open-access journal PLOS ONE ... and colleagues. , Octopuses typically have a single reproductive ... take care of their fertilized eggs until they hatch. ... to 3 months, but little is known about the ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... College Park, Md. (April 6, 2011) -- Most people experience X-ray ... tumor or blood clot. But in the lab of Dr. Quin ... a novel use of CT scanners as part of an agriculture ... a conveyor belt went little potted rice plants in an automated ...
... NY, April 6, 2011 The successful use ... and reduce the risk of neurological consequences following ... premier issue of Therapeutic Hypothermia and Temperature ... by Mary Ann Liebert, Inc. This groundbreaking new ...
... affects intake of caffeine, the most widely consumed stimulant in ... from the National Cancer Institute, Harvard School of Public Health, ... at Chapel Hill examined genetic variation across the entire genome ... in the open-access journal PLoS Genetics . ...
Cached Biology News:Seeing rice with X-rays may improve crop yields 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 3
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
... kit is a sample preparation kit for ... removal of detergents, phenolic compounds, salts, and ... dilute samples. The kit procedure involves a ... tissue or cells, plant leaves, E. coli, ...
... is intended for first-time users of the PROTEAN ... includes a protein sample and reagents sufficient to ... 17 cm, ten 11 cm, or sixteen 7 ... precast SDS-PAGE gels and gels stains are not ...
... Immunogen : Fusion protein ... 474-970 of human Mi-2 Formulation: ... NaCl, 0.035% sodium azide, containing ... evaluated by immunoblot on Hela ...
Biology Products: